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ARTICLE INFO ABSTRACT
Introduction: Antipsychotics are the mainstay of treatment in schizophrenia. First-generation and
second-generation antipsychotics are available as oral and depot formulations. The aim of this study
was to compare the relapse rate in patients with schizophrenia treated with depot and oral
antipsychotics.
Methods: All patients diagnosed with schizophrenia under the Top End Mental Health Service in
Darwin, Australia during a period of five years were included. Their medications and history of
relapses were retrieved from electronic records. Mean relapses-per-month was calculated and
compared using the independent t-test and ANOVA.
Results and discussion: The study sample contained 193 patients; 137 were males. The mean
relapses-per-month for oral formulations was significantly higher than for depot formulations.
Second-generation antipsychotic depot formulations had significantly reduced mean relapses-per-
month compared to oral second-generation formulations. The mean relapses-per-month for first-
generation antipsychotics depot was not significantly different from first-generation depot
formulations. First-generation antipsychotics depot formulations were significantly more effective
than oral second-generation. Zuclopenthixol appeared to be the best first-generation antipsychotics
depot compared to flupenazine and flupenthixol. First-generation antipsychotics depot formulations
were equally effective as Second-generation antipsychotics depot formulations.
Conclusion: Depot formulations overcome some of the adherence problems with oral therapy, and the
resultant continuous therapy is effective in reducing relapse rates.
Copyright © 2018 Mahesh K.H.D et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The Swiss psychiatrist, Eugen Bleuler, coined the term,
"schizophrenia" in 1911. In addition, he was the first to
classify the symptoms of schizophrenia as "positive" or
"negative." The word "schizophrenia" has a Greek origin,
which is schizo (split) and phrene (mind) to describe the
fragmented thinking of people with the disorder1. Other than a
difference in the duration of symptoms to meet the
requirement for diagnosis (6 months for DSM-V and 1 month
for ICD-10), both classification systems share substantial
similarities in their diagnostic criteria.
A key factor in management is the occurrence of relapses
during the course of the disease and associated deterioration in
brain functioning, making prevention a major treatment goal.
Relapse represents a significant burden to all healthcare
systems including the high cost of hospital care, post hospital
follow-up and medication costs2,3. They also cause
deterioration of the psychosocial well-being of the individual,
due to impairment of the global functional level4,5. They affect
the individual’s scholastic skills, occupation and interpersonal
relationships5,6. Further, the stigma and discrimination
associated with mental illness tends to worsen2,4. Eventually,
individuals with schizophrenia and frequent relapses carry a
significant risk of suicide7.  Improving medication adherence
is key to relapse prevention5,8, with a 2–6 times higher risk
without medication4,9,10-12.
Reasons for medication non-adherence include; willful refusal,
forgetfulness, disorganization, lack of insight, and cognitive
dysfunction. Additional factors may be; stigma, adverse effects
of medication, cost, and lack of perceived efficacy13,14.
Improving adherence to psychotropic medication, requires the
choice of an effective and safe antipsychotic agent and to
optimize treatment according to the response and its
tolerability to the individual2. However, the choice of
medication is complicated by the variety of available
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pharmaceuticals and specific considerations for the unique
differences in patients’ individualized response to the same
medication, both clinical outcomes and side effects15. Once an
antipsychotic medication is selected, the challenge is the mode
of delivery and effective dose for an individual. There are two
main routes for administration of antipsychotic medications;
oral (tablets) and intramuscular (depot/ long acting injectable
preparations).
Evidence suggests that depot antipsychotics are more effective
in reducing relapses in schizophrenia1,16-20. They are
recommended to treat non-adherent patients21. However,
patients and clinicians are sometimes reluctant to use them
because of stigma, needle pain, time constraints, side effect
concerns and the cost22.
While this study was conducted in Australia, the intention was
to relate the findings to the Sri Lankan situation where the
principle researcher resides. In the Sri Lankan context, both
first-generation antipsychotics (FGA) and second-generation
(SGA) antipsychotics are prescribed either in oral, depot or
both forms. Among oral FGA, the more commonly used
medications are chlorpromazine, haloperidol and
trifluoperazine while commonly used depot FGA are
fluphenazine, flupenthixol and zuclopenthixol.
The more frequently prescribed oral SGA preparations are
olanzapine, risperidone, quetiapine and aripiprazole. SGA
depot preparations of risperidone, paliperidone, olanzapine and
aripiprazole are not used in government hospitals in Sri Lanka
mainly due to their cost. SGA are sometimes used in the
private sector. Some researchers suggest that the SGAs are
superior in reducing relapses compare to FGAs. This study
aimed to compare the relapse rate with oral and depot
antipsychotics and to examine the relapse rates among
different antipsychotics.
METHODS
This study was a retrospective comparative study reviewing
medical records of patients who were diagnosed with
schizophrenia and who were referred to one of the two mental
health clinics in Darwin in the Northern Territory (NT) of
Australia. All patients diagnosed with schizophrenia and
referred during the period of January 2010 to December 2014
were included in this study.
Inclusion criteria
 Patients meeting ICD-10 diagnostic criteria for
schizophrenia and being treated for the disorder.
 Patients who were on a particular oral or depot
medication continuously at least for 3 months.
 Patients who remained under the care of the service for a
minimum period of one year.
 Exclusion criteria
 Patients who dropped out of treatment in less than 12
months.
 Patients for whom the diagnosis was subsequently
changed from schizophrenia to other psychotic disorders
(e.g. schizoaffective disorder, substance induced
psychosis, delusional disorder, schizophreniform
disorder).
 Patients who received combination therapy (i.e. oral and
depot medication simultaneously).
 Patients who changed the treatment modality from oral to
depot of a particular medication or vice versa in less than
3 months.
 Patients who had poor compliance to medications
(patients who were not on regular treatment for at least
three months of a particular medication) were excluded.
The study sample was selected, and de-identified, by a
consultant psychiatrist in the mental health clinic. Their past
medical records in the electronic record system, the
Community Care Information System (CCIS) were reviewed
to retrieve data on socio demographic characteristics,
medications and the history of relapses. CCIS, which is the
electronic database, stores the records of all psychiatric
patients of the NT. It contains information on presenting
history, diagnosis, past and present medications, information
on relapses and hospitalizations, and assessment details from
monthly reviews, including a mental state examination.
Recorded diagnoses within CCIS are based upon the ICD-10
classification system. CCIS also contains all the updated
records of patients since their initial referral date to the service.
To reduce the confounding effects of length of the follow up
period on frequency of relapse episodes, a mean relapse per
month (MRM) index was calculated8.
The lowest numerical value that could be obtained for MRM is
0 and it is assigned when there are no relapses recorded. A
lower MRM value implies a low relapse rates and vice versa.
Ethical approval was obtained from the Ethics Review
Committee of the Menzies School of Health Research, Darwin,
Australia. Permission to conduct this research was obtained
from the Director of the Top End Mental Health Service and
the Medical Director of the Royal Darwin Hospital to which
the clinics are affiliated. The data were analysed using SPSS,
version 23, (IBM Analytics NY,USA). Descriptive statistics
including frequencies, means and standard deviations (SD)
were studied for each variable. The association of both oral
and depot antipsychotic formulations with the relapse rate
were evaluated by an independent t-test. The significance of
each medication in reducing relapses was estimated using
ANOVA. p<0.05 was considered as statistically significant.
Data is presented as percentages and by appropriate diagrams
and charts.
RESULTS
Socio-demography
The study sample consisted of 193 patients (70.98% males and
29.02% females), participants between 19 and 69 years of age
(Figure 1). Alcohol consumption and illicit substance use
were assessed for all patients. Amongst males, 71.5%
consumed alcohol and 34.3% also used illicit substances.
Among females, 19.6% consumed alcohol and 10.7% used
illicit substances. Further, 28.5% of males and 80.4% of
females in the sample did not consume either alcohol or
substances. Many patients experienced different medications
during the five-year study period with the intention of
improving therapeutic outcome. For inclusion in the study,
patients required to be treated with a particular medication for
more than 3 months during the study period. In the instances
Number of relapses
Follow up time (month)
MRM index =
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where patients had been treated with more than one drug
during the study period with no overlap of medication, each
medication trial was considered as a separate ‘case’ in data
analysis. The Mean MRM Index was calculated for each
medication as well as for the different preparations of each
medication. Table 1.
Comparison of oral and depot antipsychotics
The mean MRM of oral and depot antipsychotics in the total
sample were compared using an independent sample t-test.
Patients receiving clozapine were excluded from this
calculation. There were 188 cases on oral and 237 cases on
depot medications in the sample. The mean MRM of oral
medications was significantly higher (p<0.0001) compared to
depot medications (Table 2). This suggests that oral
antipsychotics were less effective than depot antipsychotics in
controlling relapses in patients with schizophrenia.
The comparison of MRMs between oral and depot FGA
medications are listed in table 3. The number of cases reported
for oral FGAs were very low (n=10) compared to depot FGAs
(n=94). Therefore, a random sample of depot FGA cases
(n=10) were compared with oral FGAs using the independent
sample t-test. The results indicate that the mean MRM of oral
and depot FGAs were not significantly different (p>0.05).
A total of 321 cases were reported for SGAs therapy and
among them, 178 were for oral medications while 143 were for
depot preparations. Using the independent sample t-test,
results indicate that depot SGAs significantly reduced
(p<0.0001) MRM compared to oral SGAs in patients with
schizophrenia (Table 4).
The comparison of MRMs between oral FGA and SGAs is
illustrated in table 5. The number of cases on oral FGA was
relatively low compared to oral SGA cases, so again, a random
sample (n=10) of oral SGAs were compared with oral FGAs
using the independent t-test. The results indicated no
significant difference between the mean MRM (±SD) of oral
FGAs (0.0542 ± 0.0519) and oral SGAs (0.0880 ± 0.0412,
p>0.05)
The MRM in patients on depot FGAs and SGAs were analysed
by independent sample t-test. There were 94 cases reported for
FGAs and 143 for SGAs. Table 6 illustrates the mean MRM of
each group. There was no significant difference (p>0.05).
Since the number of cases was not equal for the two drug
groups, a random sample of 94 SGAs cases was compared
with the total depot FGAs cases, further confirming no
significant difference between the groups(p>0.05).
Depot FGAs and oral SGAs were compared indicating that
depot FGAs (0.0570 ± 0.0506) were significantly more
effective (p<0.0001) than oral SGAs (0.1071 ± 0.0491) in
reducing the relapse rate.
Conversely, a random sample of depot SGAs cases was
compared with cases on oral FGAs showing no significant
difference (p>0.05) between mean the MRM for depot SGAs
and oral FGAs medications (Table 8).
The mean MRM of patients treated with clozapine was
compared with depot FGAs and SGAs by one-way ANOVA
test, followed Bonferroni post-hoc test. The mean MRM of
clozapine treated cases was significantly lower when
compared to the mean MRM of both depots FGAs (p<0.05)
and SGAs (p<0.05) (Table 9).
Using one-way ANOVA followed by Bonferroni post-hoc test
to compare clozapine cases with oral FGAs and SGAs
revealed the mean MRM of clozapine treated patients was
significantly lower compared to the MRM of oral SGAs
treated cases (p<0.05). There was no significant difference
between the mean MRM of clozapine and oral FGAs treated
Table 1 Frequencies and mean MRMs of each medication
Medication
type Medication
Mode of
administration
Number of
cases
Mean of MRM
(SD)
SGA
Aripiprazole Oral 17 0.1042 (0.0997)
Aripiprazole Depot 2 0.0000 (0.0000)
Olanzapine Oral 65 0.1087 (0.0471)
Paliperidone Oral 25 0.1030 (0.0338)
Paliperidone Depot 72 0.0423 (0.0454)
Quetiapine Oral 15 0.0773 (0.0331)
Risperidone Oral 50 0.1058 (0.0271)
Risperidone Depot 69 0.0697 (0.0432)
Ziprasidone Oral 1 Not reported
Amisulpride Oral 5 0.0886 (0.0529)
Clozapine Oral 57 0.0171 (0.0330)
FGA
Chlorpromazine Oral 8 0.0552 (0.0523)
Flupenazine Depot 13 0.0903 (0.0425)
Flupenthixol Depot 20 0.0806 (0.0568)
Haloperidol Oral 2 0.0500 (0.0707)
Haloperidol Depot 5 0.0467(0.0462)
Zuclopenthixol Depot 56 0.0417 (0.0443)
Table 2 Comparison of oral and depot antipsychotics
Medication type Frequency Mean MRM SD SEM
Oral 188 0.1003 0.0495 0.0036
Depot 237 0.0557 0.0480 0.0031
Table  3 Comparison of oral and depot FGA formulations
Medication type Frequency Mean MRM SD SEM
FGA oral 10 0.0542 0.0519 0.0164
FGA Depot 94 0.0570 0.0506 0.0052
Table 4 Comparison of oral SGAs and depot SGAs
Medication type Frequency Mean MRM SD SEM
SGA oral 178 0.1029 0.0482 0.0036
SGA Depot 143 0.0549 0.0464 0.0039
Table 5 Comparison of FGA and SGA oral antipsychotics
Drug category Frequency Mean MRM SD SEM
FGA oral 10 0.0542 0.0519 0.0164
SGA oral 178 0.1029 0.0482 0.0036
Table 6 Comparison of MRM in patients with Depot
preparations
Drug category Frequency Mean MRM SD SEM
FGA depot 94 0.0570 0.0506 0.0052
SGA depot 143 0.0549 0.0464 0.0039
Table 7 Comparison of oral SGAs and depot FGAs
Drug category Frequency Mean MRM SD SEM
FGA depot 94 0.0570 0.0506 0.0052
SGA oral 178 0.1029 0.0482 0.0036
Table 8 Comparison of oral FGA and depot SGAs
Drug category Frequency Mean MRM SD SEM
FGA oral 10 0.0542 0.0519 0.0164
SGA depot 143 0.0549 0.0464 0.0039
Table 9 Comparison of clozapine and depots antipsychotics
Drug category Frequency Mean SD SE Minimum Maximum
FGA depot 94 0.0570 0.0506 0.0052 0.0000 0.2500
SGA depot 143 0.0549 0.0464 0.0039 0.0000 0.2000
Clozapine 56 0.0174 0.0332 0.0044 0.0000 0.2000
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cases (p>0.05). However, the sample size of oral FGAs treated
cases was small (n=10) (Table 10).
Table 11 shows the mean MRM of different oral SGAs. This
sample did not follow the Levens statistics homogeneity of
variance rule (p<0.0001) and hence, the independent samples
Kruksal Walis test was performed to assess the significant
differences in distribution of MRM across the groups. This
indicated no significant difference (p=0.106) between the
SGAs at the 95% confidence interval.
Three depot SGAs were used in the treatment of patients with
schizophrenia in this study (Table 12). The sample size for
aripiprazole was small and it was considered inappropriate to
include in this analysis. The mean MRM of paliperidone and
risperidone were compared using the independent t-test
showing that the mean MRM of paliperidone treated patients
was significantly lower than that of risperidone (p< 0.0001).
Comparison of depot FGAs
Flupenazine, flupenthixol, haloperidol and zuclopenthixol
were the depot FGAs used to treat patients with schizophrenia
in this study sample. The mean MRM of each medication is
listed in table 14. Means of these four medications were
compared by One-way ANOVA test followed by Bonferroni
post-hoc test. The mean MRM of zuclopenthixol was
significantly lower compared to both flupenazine (p=0.007)
and flupenthixol (p=0.012).
Comparison of MRM of patients treated with both oral and
depot antipsychotics
The sample contained 114 patients who had been treated with
both oral and depot medications at different times during the
study period. The MRM of these patients were compared using
the paired sample t-test. The mean MRM of depot
antipsychotic medications was significantly lower than oral
antipsychotic medications (p<0.05) as indicated in (Table 15).
DISCUSSION
In schizophrenia, a health professional’s main intention is to
prevent relapses and maintain functional status and wellbeing8.
There are modifiable and non-modifiable risk factors
associated with the relapse rate of patients with schizophrenia.
Age, gender and genetic predisposition are important among
non-modifiable risk factors, while medication adherence,
substance use and life stresses are predominant in modifiable
risk factors8.
Selecting an effective, safe and well tolerated antipsychotic
agent is challenging at times due to the diversity of available
medications and specific considerations for every individual
patient15.  This retrospective comparative study was conducted
to examine the relative beneficial effects of using depot
preparations compared with oral antipsychotic medications.
The relapse rates of patients with schizophrenia who were on
either oral or depot antipsychotic medications were compared
initially. It revealed that overall, depot antipsychotics appeared
to be more effective than oral antipsychotics in controlling
relapses in schizophrenia in this patient population. The
patients who were treated with both oral and depot
antipsychotic medications at different times were examined to
try to reduce bias of comparing different individuals. This also
indicated that depot medications were superior in controlling
relapses. This is in keeping with other similar studies. Leuchet
et al. demonstrated that, depot antipsychotic drugs reduce the
relapse rate by 30%23. Further, a recent mirror-image study
showed long acting injectables were superior to oral
medications in reducing hospitalization24. However, the impact
of compliance in the superiority of depot preparations over
orals in preventing relapses is difficult to quantify and this is a
confounding factor in this study as well. Side effects and lack
of insight are the two main factors contributing to medication
non-adherence in patients with schizophrenia25, with 66% of
patients cited adverse effects as their primary reason for non-
adherence. Depot formulations are considered the most
successful pharmacological intervention to address non-
adherence in schizophrenia13,26. Depot preparations are
administered by a health care professional (doctor or a nurse)
and therefore, missing an appointment for their injection is
easily noticeable27,28, and once the medication has been
injected, the effects will be there for an extended period,
whether the patient finds the side-effects acceptable or not. In
contrast, compliance with oral medication can be erratic.  They
are usually taken at home and not monitored. Parenteral
preparations are not influenced by first-pass metabolism and
are efficient in maintaining optimum plasma levels.
Consequently, these long acting injectable preparations are
often recommended for individuals who have known poor
adherence patterns for oral antipsychotics. Some studies
demonstrate that the risk of re-hospitalization in patients
receiving long acting antipsychotic injections was two-thirds
lower than patients receiving the oral equivalent29,30.  The
results of this study again confirmed the superiority of depot
SGAs over the oral preparations of the same medication in
controlling relapses. A post-hoc analysis of trials showed that
the risk of relapse was higher among patients receiving oral
paliperidone compared to depot paliperidone31. Further, a two-
year prospective study showed that the Risperidone depot
signiﬁcantly reduced relapse and improved compliance,
relative to oral risperidone32.This study demonstrated a general
pattern where depot SGAs appear superior to oral SGAs. A
study which compared the effectiveness of individual
Table10 Comparison of Clozapine and other oral
antipsychotics
Drug categoryFrequencyMean MRM SD SE Minimum Maximum
FGA oral 10 0.0542 0.0519 0.0164 0.0000 0.1250
SGA oral 178 0.1029 0.0482 0.0036 0.0000 0.3333
Clozapine 56 0.0174 0.0332 0.0044 0.0000 0.2000
Table 11 Comparison of oral SGAs
MedicationFrequency Mean MRM SD SE Minimum Maximum
Aripiprazole 17 0.1042 0.0997 0.0242 0.0000 0.3333
Olanzapine 65 0.1087 0.0471 0.0058 0.0000 0.3333
Paliperidone 25 0.1030 0.0338 0.0068 0.0000 0.1667
Quetiapine 15 0.0773 0.0331 0.0085 0.0000 0.1250
Risperidone 50 0.1058 0.0271 0.0038 0.0526 0.1667
Amisulpride 5 0.0886 0.0529 0.0236 0.0000 0.1429
Table 12 Comparison of depot SGAs
Medication FrequencyMean MRM SD SE MinimumMaximum
Aripiprazole 2 0.0000 0.0000 0.0000 0.0000 0.0000
Paliperidone 72 0.0423 0.0454 0.0054 0.0000 0.2000
Risperidone 69 0.0697 0.0432 0.0052 0.0000 0.1667
Table 14 Comparison of depot FGAs
Medication FrequencyMean MRM SD SE Minimum Maximum
Flupenazine 13 0.0903 0.0425 0.0118 0.0000 0.1667
Flupenthixol 20 0.0806 0.0568 0.0127 0.0000 0.2500
Haloperidol 5 0.0467 0.0462 0.0207 0.0000 0.1000
Zuclopenthixol 56 0.0417 0.0443 0.0059 0.0000 0.2000
Table 15 Comparison of MRM in patients treated with both
oral and depot antipsychotics
Medication type Mean MRM Frequency SD SEM
oral 0.1048 114 0.0459 0.0043
depot 0.0441 114 0.0366 0.0034
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medications revealed a significant advantage of depot
risperidone (16% relapse rate) over oral quetiapine (31%
relapse rate)33. Some studies which used hospitalization as a
measure of the relapse rate noted a 46% relapse rate for long
acting risperidone and 43% for oral aripiprazole34. However, a
2-year study by Rosenheck et al.35 revealed that Risperidone
depot did not signiﬁcantly reduce relapses over oral
antipsychotics.
Among the six oral SGAs, olanzapine and risperidone were the
most commonly used medications in this study sample.
However, the effectiveness of individual orals SGAs in
controlling psychotic relapses was similar among the different
medications. Although quetiapine showed the lowest relapse
rate among oral SGAs, only a small number of patients (n=15)
were treated with it, so its superiority over other oral SGAs is
not established by this study.
Long acting injectable preparations of paliperidone and
risperidone were the most used SGAs in this study sample.
Among the depot SGAs preparations, paliperidone depot
appears to have a superior effect over risperidone in
controlling relapses in schizophrenia. Similar results,
indicating that the paliperidone depot significantly reduces the
relapse rate of schizophrenia compared to risperidone and
olanzapine depots were demonstrated by Bishara36.
Aripiprazole depot has only been recently introduced to the
public health system in Australia and the sample contained
only two patients on this drug, so this requires further study.
The usage of oral FGAs is limited at present. In this study,
only oral chlorpromazine and haloperidol were prescribed to
the sample population. Only ten patients in this sample were
treated with these oral FGAs. This appears to be mainly due to
the FGAs side effects profile.
The prescription numbers for depot FGAs was comparatively
high in this study. Among them, the zuclopenthixol depot was
the most frequently used, being administered to 56 patients.
Haloperidol was the least used FGA depot, being used on only
five patients, possibly due to its likelihood of producing side
effects. This was previously noted in a four-month study
among inpatients with schizophrenia that demonstrated that
haloperidol depot was associated with only a marginally better
efficacy but more extra pyramidal side effects, compared to
oral haloperidol30.
This study suggested differences in effectiveness between
depot FGAs and oral FGAs, but the small number of patients
on oral FGAs precludes any definitive conclusions being
drawn from this comparison.  Among the depot FGAs used in
this sample, zuclopenthixol showed a greater effect in
controlling relapses compared to flupenthixol, fluphenazine
and haloperidol.  A 21-month study by Del Giudice et al.37
showed that fuphenazine depot was superior to oral
Fluphenazine in reducing relapses in patients with
schizophrenia30,37. There is also evidence to suggest that
patients treated with haloperidol or fluphenazine long-acting
injections had a signiﬁcantly longer mean time to medication
discontinuation and were twice as likely to stay on medication,
compared to patients treated with oral haloperidol or
fuphenazine30. The data from this study is insufficient to verify
this.  Some studies have demonstrated a superior effect of oral
SGAs over oral FGAs in relapse prevention. This study did not
show a significant effect with oral SGAs due to the very small
sample of patients treated with FGA’s, however the very low
numbers be explained by the previous study findings.
Antipsychotic therapy evolved from first generation to second
generation agents gradually as the latter group gave rise to
comparatively less side effects and hence encouraged better
adherence. A meta-analysis by Leucht et al.11 compared the
effectiveness of nine second generation antipsychotics with
first generation antipsychotics in schizophrenia. The results
revealed that second generation antipsychotics were
significantly more effective than first generation
antipsychotics. In this study, though there were patients treated
with depot FGAs and SGAs, no superiority was observed in
either medication groups in reducing relapses of schizophrenia.
In contrast, depot FGAs demonstrated dominance over oral
SGAs in controlling relapses in patients with schizophrenia.
The results of a systematic review, carried out to compare
depot FGAs with both oral FGAs and SGAs, showed an
overall clinical advantage in preventing relapses among depot
FGAs38. However, evidence over the years does not provide
unequivocal data in the use of long acting injectable FGAs25,38.
Kishimoto et al. reported an overall relapse rate of 37% among
patients receiving FGAs, while the relapse rate of those on
SGAs was 29%24.
The results of this study suggest that zuclopenthixol is the
most effective FGA depot in preventing relapses of
schizophrenia. Substance and alcohol abuse is common among
patients with schizophrenia and relapses show a strong
correlation with substance use. In this study a number of
patients used substances and alcohol, although the percentage
of women using alcohol or substances was comparatively low.
However, as records were obtained retrospectively, they
depended on patients disclosing substance misuse and may not
have been entirely accurate. A follow up study of patients with
schizophrenia showed that 24% of individuals abused either
alcohol or illicit substances and 72% of illicit substance users
had experienced at least one episode of hospitalization30.
Extrapolating to the Sri Lankan health environment, depot
preparations are used commonly in managing schizophrenia.
Sri Lanka does not have a well-established community mental
health care network and few community treatment centers. It
does not possess a comprehensive network of case managers.
Further, with limited financial, human and infrastructure
resources for mental health there is no system to effectively
monitor medication compliance among patients. Therefore,
treatment dropouts are common. Moreover, patients are
reluctant to use long-term medications due to stigma.
Considering all these factors, the use of depot antipsychotic
medications could be considered as a more reliable and
effective tool to ensure patient compliance with treatment for a
country such as Sri Lanka. This in turn could prove cost-
effective by preventing relapses and potential hospital
admissions. Depot FGAs are widely used in Sri Lanka.
However, depot SGA formulations are less popular due to
higher acquisition cost. They are occasionally prescribed in the
private sector, but use in the government hospitals is unlikely
in the near future. The finding in this study that depot FGAs
were equally effective as depot SGAs encourages the
continued use of depot FGAs in the Sri Lankan setting which
can be sustained due to its lower cost.This study was
conducted in a population outside Sri Lanka. However, the
study sample was mostly of Asian descent (mainly from
China, India, Pakistan, Bangladesh, Sri Lanka and Nepal)
which minimized the biological and cultural factors that could
affect the results of this study.
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CONCLUSION
The main findings of this study are
1. Depot antipsychotics were superior to oral antipsychotics
in reducing relapses in patients with schizophrenia.
2. Depot SGAs were more effective than oral SGAs in
reducing relapses in patients with schizophrenia.
3. Depot FGAs were equally effective as depot SGAs in
reducing relapses in patients with schizophrenia.
Limitations
The main limitations of this study are
1. Data collection was retrospective and done only over a
five-year study period.
2. The sample consisted of a low number of patients treated
with oral FGAs.
3. Effective comparison of newer medications such as
aripiprazole depot could not be done because it was
introduced only recently and was used on a limited
number of patients.
Recommendations
It would be ideal to conduct a similar study in a Sri Lankan
population to further evaluate the findings of this study.
This study suggests that the use of depot FGAs could be as
effective as using depot SGAs. A study directly comparing
these two treatment modalities conducted in a Sri Lankan
setting could yield valuable findings which could be utilised to
plan treatment strategies at a national level in Sri Lanka.
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